FOXO4

Aging tissues accumulate cells that no longer divide but refuse to die. Through their so-called SASP (senescence-associated secretory phenotype), these senescent cells release pro-inflammatory messengers and disturb the function of the surrounding tissue. FOXO4-DRI is one of the best known tools for removing precisely these cells.

The senescent cell's trick: it holds the protein p53 in place with the help of FOXO4 and thereby suppresses its own apoptosis program. FOXO4-DRI wedges itself into this bond, p53 is freed and can lead the cell into programmed death. Because only senescent cells depend on FOXO4 in this way, the effect stays confined to them in preclinical models.

The suffix DRI stands for D-retro-inverso: the peptide is assembled from D-amino acids in reversed order. Proteases barely recognize this mirror form, which is why the molecule stays stable far longer than a natural L-peptide.

Results from the literature:

• Cell 2017 (Peter de Keizer lab): Characterization of the mechanism; in mouse aging models better kidney function, more physical activity and denser fur again.
• Leydig cells (2020): In naturally aged mice, senescent Leydig cells were selectively driven into apoptosis, the testicular environment improved and the age-related drop in testosterone output was reversed.
• Human chondrocytes (2021): In extensively expanded cartilage cells the peptide cleared over 50 percent of the cells and pushed the senescence level down; minimally expanded cells stayed untouched. The capacity to form cartilage did not improve as a result, however.

The data are preclinical; clinical trials are at the beginning.

A peptide that deliberately sends cells to their death belongs in a different category from peptides conceived as regenerative. That shapes the entire risk assessment.

• Active cell death: The release of p53 starts the apoptosis program. In animal models this hits senescent cells; whether that accuracy holds in humans, nobody has tested.
• Human data: Clinical trials are in early phases. The literature yields no statements on tolerability or dose in humans.
• Injection site: With parenteral dosing, local irritation is to be expected.
• Systemic reactions: Animal models describe transient whole-organism reactions after dosing.
• Depth of intervention: Even though the preclinical data remain limited to senescent cells, a pro-apoptotic mechanism naturally carries a different risk profile.

This summary is no substitute for medical advice.

• Targeted apoptosis of senescent cells via FOXO4-p53 - the original paper describing mechanism and effects in mouse aging models.
• FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice - shows the selective apoptosis of senescent Leydig cells and the recovery of testosterone output in aged mice.
• Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes - demonstrates the removal of senescent cells from expanded human cartilage cells without any gain in cartilage-forming potential.